How to legally get Strattera online in Florida

Understanding Non-Stimulant ADHD Medication via Telehealth

Are you considering non-stimulant ADHD treatment through telehealth? With evolving regulations and varying state laws, navigating the telehealth landscape for medications like Strattera (atomoxetine) can be confusing. This comprehensive guide breaks down what you need to know about accessing non-stimulant ADHD medications through telehealth in 2025.

What Makes Non-Stimulant ADHD Medications Different?

Unlike ADHD stimulants (such as Adderall, Ritalin, or Vyvanse), medications like Strattera are not classified as controlled substances by the Drug Enforcement Administration (DEA). This key distinction means they:

• Don’t carry the same legal restrictions as stimulants
• Aren’t subject to the DEA’s special in-person examination requirements
• Can typically be prescribed more flexibly via telehealth
• Allow for longer prescription supplies (often up to 90 days)
• Permit refills without requiring a new prescription each time

For patients seeking ADHD treatment through telehealth, non-stimulants can offer a more accessible option with fewer regulatory hurdles.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Regulations: Current Status

As of December 2025, the DEA’s COVID-era telehealth flexibilities remain in effect through December 31, 2025, allowing controlled substances (including stimulants) to be prescribed via telehealth without a prior in-person examination. However, these rules primarily impact stimulant medications—not non-stimulants like Strattera.

For non-stimulant ADHD medications:

• No federal restriction exists on telehealth prescribing
• No in-person visit is required by federal law
• The Ryan Haight Act’s in-person requirements don’t apply

Important note: While the current DEA flexibilities for controlled substances are set to expire on December 31, 2025, this expiration will not affect non-stimulant medications. Even if the Ryan Haight Act’s in-person requirements resume for stimulants in 2026, medications like Strattera will remain available via telehealth.

State-by-State Telehealth Rules for Non-Stimulant ADHD Medications

While federal law permits telehealth prescribing of non-stimulants, state laws add another layer of regulation. Here’s how telehealth rules for non-stimulant ADHD medications vary across key states:

California

• Telehealth allowed? Yes, fully permitted
• In-person exam required? No state requirement for non-controlled medications
• Prescription monitoring? Not required for non-stimulants (only for controlled substances)
• Provider types: Both physicians and nurse practitioners can prescribe non-stimulants via telehealth

California remains one of the most telehealth-friendly states, with proposed legislation (AB 1503) in 2025 to further clarify that telehealth examinations satisfy requirements for prescribing medications.

New York

• Telehealth allowed? Yes
• In-person exam required? None for non-stimulants (NY’s 2025 in-person rule only applies to controlled substances)
• Prescription monitoring? Not mandated for non-controlled medications
• Provider types: Physicians and nurse practitioners with independent practice authority can prescribe

While New York implemented stricter rules for controlled substances in 2025, non-stimulant ADHD medications remain accessible through telehealth without in-person requirements.

Florida

• Telehealth allowed? Yes
• In-person exam required? No requirement for non-stimulants
• Prescription monitoring? Not required for non-controlled medications
• Provider types: Physicians can prescribe independently; NPs/PAs require physician supervision

Florida’s telehealth laws have been permanent since 2022, providing stable access to non-stimulant ADHD medications via telehealth.

Texas

• Telehealth allowed? Yes, especially for mental health
• In-person exam required? No requirement for non-stimulants
• Prescription monitoring? Not mandated for non-controlled medications
• Provider types: Physicians can prescribe; NPs/PAs face restrictions on controlled substances but can prescribe non-stimulants under physician supervision

Texas explicitly allows telemedicine for behavioral health and chronic care management, making it conducive to telehealth ADHD treatment with non-stimulants.

Alabama

• Telehealth allowed? Yes, but with stricter oversight
• In-person exam required? Periodic (within 12 months) for ongoing telehealth care, though mental health services are exempt from this requirement
• Prescription monitoring? Not required for non-stimulants
• Provider types: Collaborative practice for NPs/PAs

Alabama has one of the stricter telehealth frameworks, but its requirement for annual in-person visits is waived for mental health services, which typically includes ADHD care.

New Hampshire

• Telehealth allowed? Yes, recently expanded
• In-person exam required? Annual evaluation (can be via telehealth) for controlled medications; none for non-stimulants
• Prescription monitoring? Not required for non-stimulants
• Provider types: Independent NP practice; PAs require supervision

New Hampshire’s SB 252 (effective August 2025) greatly expanded telehealth flexibility by removing in-person requirements for initial prescribing.

Georgia

• Telehealth allowed? Yes
• In-person exam required? None for non-stimulants
• Prescription monitoring? Not required for non-controlled medications
• Provider types: Physicians can prescribe; NPs/PAs have restricted formularies under collaboration

Georgia places significant restrictions on NP/PA prescribing of controlled substances, but non-stimulants can be prescribed via telehealth under collaborative practice.

Strattera (Atomoxetine) Quick Reference

Key Considerations for Patients

Eligibility for Telehealth ADHD Treatment

Reputable telehealth providers conduct comprehensive evaluations before prescribing any ADHD medication. For non-stimulants like Strattera, eligibility criteria typically include:

• A thorough evaluation using DSM-5 diagnostic criteria
• Assessment of medical history and current medications
• Screening for contraindications (such as narrow-angle glaucoma or recent MAOI use)
• Evaluation of cardiovascular health

Not everyone is an ideal candidate for telehealth ADHD treatment. You may be referred for in-person care if you have:

• Complex co-occurring mental health conditions
• Serious cardiovascular issues
• Significant liver problems
• A history that requires more extensive in-person assessment

The Telehealth Evaluation Process

When seeking non-stimulant ADHD medication through telehealth, expect:

1. Comprehensive intake: Questionnaires about symptoms, medical history, and prior treatments
2. Video consultation: A thorough interview with a licensed provider
3. Documentation review: The provider may request previous medical records, particularly if you’ve been diagnosed before
4. Discussion of options: Including non-stimulant medications like Strattera and their benefits/risks
5. Prescription and monitoring plan: If appropriate, with regular follow-ups to assess progress

Provider Types and Prescribing Authority

Different types of providers can prescribe non-stimulant ADHD medications via telehealth:

• Physicians (MD/DO): Can prescribe in all states
• Nurse Practitioners: Can prescribe non-stimulants in all states, though some require physician collaboration
• Physician Assistants: Can prescribe with physician supervision, with state-specific variations in autonomy

At Klarity, we connect patients with appropriately licensed providers who can legally prescribe in your state, ensuring you receive care that complies with all regulations.

Common Misconceptions

Several myths persist about telehealth ADHD treatment:

Myth: ‘Online ADHD prescriptions are automatic.’
Reality: Legitimate tele

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment